Thursday, 16 May 2013
The Stevenage Bioscience Catalyst, United Kingdom
Whilst biopharmaceuticals remain a major component of the global therapeutics market, the ever expanding portfolio of products losing patent protection and with increasing healthcare costs remaining a poignant issue, the opportunity for development of competing, follow on biologics remains an attractive proposition for both Biotech and Pharma companies alike. However, as these biosimilar markets are captured how we manage the life cycle of these products and target specific patient and commercial benefits to maximise our product development strategies becomes increasingly important.
This Euroscicon biosimilars conference will focus on multiple aspects of biosimilar product development to successfully deliver safe, biosimilar products to the market place.
This event has CPD accreditation
Who should attend
Specialists in regulatory strategy and affairs, Biopharmaceutical developers/manufacturers including analytics/characterisation, marketing professionals, product enabling technology development companies
Meeting Chair: Dave Simpson PhD, Director, Virodigm Ltd
This event is part of the 2013 Euroscicon BioTherapeutics Week,
to find out more see www.biotherapeutics2013.com
Event Web Site: www.regonline.co.uk/biosimilar2013
Tags: automation, Biobetter, biobetters, Biologicals, biopharmaceutical, bioreactor, Biosimilar, Biosimilarity, Biosimilars, cell line, Characterisation, CMC, Comparability, CTD, drug delivery, enabling, EU, glycan, monoclonal antibodies, next generation biologics, Process Development, Product registration, Regulatory, Similarity, technologies
Follow Us!